Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium with Oxaliplatin and Capecitabine in Advanced GI Cancer
NCT03153280Phase 1Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lithium in colorectal cancer (CRC), esophageal cancer and gastric cancer (GC), sponsored by Cancer Trials Ireland. Primary endpoint: Incidence of Dose Limiting Toxicity at 26 months. Started Jan 2022; status: terminated.
02
Drugs
lithium
03
Conditions
colorectal cancer (CRC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03153280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153280.